Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

24.43 -0.04 (-0.14%)
Streaming Delayed Price Updated: 2:13 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 850,009
Open 24.50
Bid (Size) 24.41 (1)
Ask (Size) 24.47 (5)
Prev. Close 24.47
Today's Range 23.79 - 24.69
52wk Range 19.73 - 47.32
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. 
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals
VERACYTE INC (NASDAQ:VCYT) is an undervalued biotech stock with strong financial health, solid profitability, and impressive growth prospects, making it a candidate for value investors. 
Via Chartmill

Performance

YTD
-39.6%
-39.6%
1 Month
-9.6%
-9.6%
3 Month
-22.1%
-22.1%
6 Month
-44.0%
-44.0%
1 Year
+6.1%
+6.1%

More News

Read More
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For May 7, 2025
Via Benzinga
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems
Via Benzinga
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology
Via Chartmill
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Breaking Down Veracyte: 7 Analysts Share Their Views
Via Benzinga
Veracyte Announces First Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch
Via Chartmill
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
Via Benzinga
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
From Veracyte, Inc.
Via Business Wire
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
Via Investor's Business Daily
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
From Veracyte, Inc.
Via Business Wire
Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability.
Via Chartmill
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable.
Via Chartmill
5 Analysts Assess Veracyte: What You Need To Know
Via Benzinga
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
From Veracyte, Inc.
Via Business Wire
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Via Benzinga

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 24.43
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 07/30/25 02:13 PM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 1.65B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.